 |
Justin Petrone is the editor of GenomeWeb's BioArray News and covers the microarray and biochip sector of the genomics market. E-mail Justin Petrone or follow his GenomeWeb Twitter account at @BioArrayNews. |
Despite Genotyping Growth, Expression Decline Leaves Analysts Skeptical of Affy Turnaround
November 06, 2012
Despite Genotyping Growth, Expression Decline Leaves Analysts Skeptical of Affy Turnaround
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Despite Continued Genotyping Growth, Weak Expression Sales Force Affymetrix to Suspend Guidance
May 7, 2013 / BioArray News - At JP Morgan, Affy Provides Update on Cyto FDA Submission, New Genotyping Products, Restructuring
January 15, 2013 / BioArray News - Affymetrix to Lay off 100 in Restructuring; Reports Preliminary Q4 Revenue of $84M
January 9, 2013 / GenomeWeb Daily News - People in the News: Sue Siegel, Mike Barber, Stephen Fodor, Frank Witney, Nelson Chan, and More
May 22, 2012 / BioArray News - Affy 'Reassessing' Strategy, Focus after 'Challenging' Q2, New CEO Says
August 2, 2011 / BioArray News